keyword
MENU ▼
Read by QxMD icon Read
search

teriparatide

keyword
https://www.readbyqxmd.com/read/27908253/assessment-of-bone-quality-in-osteoporosis-treatment-with-bone-anabolic-agents-really-something-new
#1
Fabio Massimo Ulivieri, Renata Caudarella, Marzia Camisasca, Daniela Maria Cabrini, Ilaria Merli, Carmelo Messina, Luca Petruccio Piodi
Osteoporosis is a chronic pathologic condition, particularly of the elderly, in which a reduction of bone mineral density (BMD) weakens bone, leading to the so-called fragility fractures, most often of spine and femur. The gold standard exam for the quantitative measurement of BMD is the dual X-ray photon absorptiometry (DXA), a radiological method. However, a relevant number of fragility fractures occurs in the range of normal BMD values, meaning that also qualitative aspects of bone play a role, namely bone architecture and bone geometry...
December 1, 2016: Current Rheumatology Reviews
https://www.readbyqxmd.com/read/27895472/safety-and-effectiveness-of-daily-teriparatide-for-osteoporosis-in-patients-with-severe-stages-of-chronic-kidney-disease-post-hoc-analysis-of-a-postmarketing-observational-study
#2
Atsushi Nishikawa, Fumito Yoshiki, Masanori Taketsuna, Kenta Kajimoto, Hiroyuki Enomoto
Teriparatide (recombinant 1-34 N-terminal sequence of human parathyroid hormone) for the treatment of osteoporosis should be prescribed with caution in patients with severe stages of chronic kidney disease (CKD). However, in clinical settings, physicians and surgeons who treat such patients have few available options. We sought to further explore the safety and effectiveness of teriparatide for the treatment of osteoporosis in Japanese patients with severe stages of CKD. This was a post hoc analysis of a postmarketing surveillance study that included patients with osteoporosis at high risk of fracture and stage 4 or 5 CKD...
2016: Clinical Interventions in Aging
https://www.readbyqxmd.com/read/27880077/teriparatide-treatment-in-elderly-patients-with-sacral-insufficiency-fracture
#3
Jun-Il Yoo, Yong-Chan Ha, Hyun-Jun Ryu, Geun-Wu Chang, Young-Kyun Lee, Moon-Jib Yoo, Kyung-Hoi Koo
CONTEXT AND OBJECTIVE: Pain-related immobility due to insufficiency fractures may result in serious complications and a high mortality rate in senile patients with pre-existing comorbidities. This study aimed to evaluate the efficacy of teriparatide in patients with sacral insufficiency fractures. DESIGN, SETTING AND PARTICIPANTS: Retrospective case-controlled single center study was performed from 2009 to 2014. 41 patients underwent radiographs, magnetic resonance imaging and/or bone scans to document sacral insufficiency fractures...
November 23, 2016: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/27859635/abaloparatide-is-an-anabolic-but-does-it-spare-resorption
#4
T J Martin, E Seeman
Abaloparatide is a novel peptide that shares aminoterminal sequence with PTHrP. It has been shown in a clinical trial to reduce vertebral and nonvertebral fracture risk and to promote bone formation in the aged osteopenic rat. It is proposed to produce its anabolic effect with less promotion of resorption than with teriparatide. This article is protected by copyright. All rights reserved.
November 18, 2016: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/27857920/effectiveness-of-osteoporosis-drug-in-postmenopausal-women-with-spinal-compression-fracture-combined-consecutive-therapy-of-teriparatide-and-raloxifene-versus-bisphosphonate-single
#5
Chang Jin Shin, Sion Kim, Chun Sik Choi, Hyun Chul Shin, Young Joon Kwon
OBJECTIVE: Bisphosphonate, a typical bone resorption inhibitor, is an important first-line drug for treating osteoporosis. Recent studies show a novel paradigm in stimulating bone formation. Teriparatide, which is composed of recombinant human parathyroid hormone, stimulates osteoblasts and induces bone regeneration. Bone mineral density (BMD) that was used before and after the treatment with anti-osteoporosis drug was compared for the effectiveness in therapy between a combination of teriparatide and selective estrogen receptor modulator (SERM), and bisphosphonate...
October 2016: Korean Journal of Neurotrauma
https://www.readbyqxmd.com/read/27852903/effects-of-teriparatide-compared-with-risedronate-on-recovery-after-pertrochanteric-hip-fracture-results-of-a-randomized-active-controlled-double-blind-clinical-trial-at-26-weeks
#6
Per Aspenberg, Jorge Malouf, Umberto Tarantino, Pedro A García-Hernández, Costantino Corradini, Søren Overgaard, Jan J Stepan, Lars Borris, Eric Lespessailles, Frede Frihagen, Kyriakos Papavasiliou, Helmut Petto, José Ramón Caeiro, Fernando Marin
BACKGROUND: Osteoporosis drugs might affect fracture-healing. We therefore studied the effects of teriparatide in comparison with risedronate on recovery after pertrochanteric hip fractures. METHODS: The study was a randomized, multicenter, active-controlled, 78-week trial comparing teriparatide (20 μg/day) with risedronate (35 mg/week) initiated within 2 weeks after fixation of a low-trauma pertrochanteric hip fracture (AO/OTA 31-A1 or 31-A2). The main inclusion criteria were a bone mineral density T-score of ≤-2...
November 16, 2016: Journal of Bone and Joint Surgery. American Volume
https://www.readbyqxmd.com/read/27847678/a-systematic-review-of-treatment-strategies-for-degenerative-lumbar-spine-fusion-surgery-in-patients-with-osteoporosis
#7
Charla R Fischer, Gregory Hanson, Melinda Eller, Ronald A Lehman
PURPOSE: To evaluate the current evidence in the literature on treatment strategies for degenerative lumbar spine fusion in patients with osteoporosis. METHODS: A systematic review of the literature from 1950 to 2015. RESULTS: The review of the literature yielded 15 studies on the effect of treatment options for osteoporosis on lumbar fusion rates. This study evaluated only degenerative lumbar spine conditions and excluded deformity patients...
December 2016: Geriatric Orthopaedic Surgery & Rehabilitation
https://www.readbyqxmd.com/read/27830384/comparison-of-the-effects-of-denosumab-between-a-native-vitamin-d-combination-and-an-active-vitamin-d-combination-in-patients-with-postmenopausal-osteoporosis
#8
Kosuke Ebina, Masafumi Kashii, Makoto Hirao, Jun Hashimoto, Takaaki Noguchi, Kota Koizumi, Kazuma Kitaguchi, Hozo Matsuoka, Toru Iwahashi, Yasunori Tsukamoto, Hideki Yoshikawa
The aim of this 12-month, retrospective study was to compare the effects of denosumab (DMAb; 60 mg subcutaneously every 6 months) plus native vitamin D (VD) (cholecalciferol) combination therapy with DMAb plus active VD analog (alfacalcidol) combination therapy in patients with postmenopausal osteoporosis. Patients [N = 127; mean age 75.6 years (range 58-93 years); 28 treatment-naïve patients, 59 patients treated with oral bisphosphonate therapy, 40 patients treated with teriparatide daily] were allocated to either (1) the DMAb plus native VD group (n = 60; cholecalciferol, 10 μg, plus calcium, 610 mg/day; 13 treatment-naïve patients, 28 patients treated with oral bisphosphonate therapy, and 19 patients treated with teriparatide daily) or (2) the DMAb plus active VD group [n = 67; alfacalcidol, 0...
November 9, 2016: Journal of Bone and Mineral Metabolism
https://www.readbyqxmd.com/read/27826127/effects-of-abaloparatide-sc-ba058-on-bone-histology-and-histomorphometry-the-active-phase-3-trial
#9
Carolina Moreira, Lorraine A Fitzpatrick, Yamei Wang, Robert R Recker
There are a number of effective treatments for osteoporosis but most are in the antiresorptive class of compounds. Abaloparatide-SC is a new osteoanabolic agent, which increased bone mineral density and lowered the risk of osteoporosis-related fractures in the phase 3 ACTIVE trial. The objective of this report is to describe the effects of abaloparatide-SC 80μg on bone histology and histomorphometry in iliac crest bone biopsies from this trial in which participants were randomized to receive blinded daily subcutaneous injections of placebo or abaloparatide-SC 80μg/d or open-label teriparatide 20μg/d for 18months...
November 5, 2016: Bone
https://www.readbyqxmd.com/read/27826025/vitamin-d-and-calcium-supplementation-for-three-years-in-postmenopausal-osteoporosis-significantly-alters-bone-mineral-and-organic-matrix-quality
#10
E P Paschalis, S Gamsjaeger, N Hassler, A Fahrleitner-Pammer, H Dobnig, J J Stepan, I Pavo, E F Eriksen, K Klaushofer
Prospective, controlled clinical trials in postmenopausal osteoporosis typically compare effects of an active drug with placebo in addition to vitamin D and calcium supplementation in both treatment arms. While clinical benefits are documented, the effect of this supplementation in the placebo arm and in clinical practice on bone material composition properties is unknown. The purpose of the present study was to evaluate these bone quality indices (specifically mineral/matrix, nanoporosity, glycosaminoglycan content, mineral maturity/crystallinity, and pyridinoline content) in patients that either received long-term vitamin D (400-1200IU) and calcium (1...
November 5, 2016: Bone
https://www.readbyqxmd.com/read/27777917/adjuvant-teriparatide-therapy-for-surgical-treatment-of-femoral-fractures-does-it-work
#11
Jung Taek Kim, Hyung Jun Jeong, Soong Joon Lee, Hee Joong Kim, Jeong Joon Yoo
PURPOSE: Atypical femoral fracture (AFF), periprosthetic femoral fracture (PPFF) and femoral nonunion (FNU) are recalcitrant challenges for orthopedic surgeons. Teriparatide (TPTD) had been demonstrated to have anabolic effects on bone in various studies. We postulated that adjuvant TPTD after operation would enhance biologic stimulation for bone formation. We investigated (1) whether the adjuvant TPTD could achieve satisfactory union rate of surgically challenging cases such as displaced AFF, PPFF and FNU; (2) whether the adjuvant TPTD could promote development of abundant callus after surgical fixation; (3) whether the adjuvant TPTD had medically serious adverse effects...
September 2016: Hip & Pelvis
https://www.readbyqxmd.com/read/27777391/-relationship-of-pharmacokinetics-changes-of-bone-turnover-markers-and-bmd-fractures-efficacy-during-treatment-with-anabolic-agents-teriparatide-daily-and-once-weekly-subcutaneous-injections
#12
Akimitsu Miyauchi
Teriparatide(recombinant human PTH1-34, 20 μg daily subcutaneous injection)has been approved for osteoporosis patients at high risk of fracture in many countries including Japan. Teriparatide daily injection therapy has been reported to increase BMD, improve microarchitecture of bone, and reduce the risk of new vertebral fractures and that of non-vertebral fractures. Pharmakokinetic(PK)study after a single Teriparatide injection of the daily dose in healthy Japanese postmenopausal women(n=18)revealed very rapid achievement of peak blood level(median of tmax=0...
2016: Clinical Calcium
https://www.readbyqxmd.com/read/27766368/anti-osteoporotic-treatments-in-france-initiation-persistence-and-switches-over-6%C3%A2-years-of-follow-up
#13
M Belhassen, C B Confavreux, B Cortet, L Lamezec, M Ginoux, E Van Ganse
: Limited information is available on anti-osteoporotic treatment initiation patterns in France. In 2006-2013, the most frequently prescribed first-line treatment class for osteoporosis was represented by bisphosphonates (alendronic acid and risedronic acid), followed by strontium ranelate. Persistence with anti-osteoporotic treatment was low, with high proportions of treatment discontinuations and switches. INTRODUCTION: This epidemiological, longitudinal study described first-line treatment initiation, persistence, switches to second-line treatment, and medical care consumption in osteoporotic patients in France during the 2007-2013 period...
October 20, 2016: Osteoporosis International
https://www.readbyqxmd.com/read/27738545/massive-preperitoneal-hematoma-after-a-subcutaneous-injection
#14
Hideki Katagiri, Kentaro Yoshikawa, Alan Kawarai Lefor, Tadao Kubota, Ken Mizokami
Preperitoneal hematomas are rare and can develop after surgery or trauma. A 74-year-old woman, receiving systemic anticoagulation, developed a massive preperitoneal hematoma after a subcutaneous injection of teriparatide using a 32-gauge, 4 mm needle. In this patient, there were two factors, the subcutaneous injection of teriparatide and systemic anticoagulation, associated with development of the hematoma. These two factors are especially significant, because they are widely used clinically. Although extremely rare, physicians must consider this potentially life-threatening complication after subcutaneous injections, especially in patients receiving anticoagulation...
2016: Case Reports in Surgery
https://www.readbyqxmd.com/read/27732335/teriparatide-treatment-in-patients-with-wnt1-or-pls3-mutation-related-early-onset-osteoporosis-a-pilot-study
#15
Ville-Valtteri Välimäki, Outi Mäkitie, Renata Pereira, Christine Laine, Katherine Wesseling-Perry, Jorma Määttä, Mikko Kirjavainen, Heli Viljakainen, Matti J Välimäki
CONTEXT: We previously identified two Finnish families with dominantly inherited, low-turnover osteoporosis caused by mutations in WNT1 or PLS3. OBJECTIVE: Design and Setting: This prospective, longitudinal, uncontrolled study was undertaken to evaluate whether patients with these mutations respond to teriparatide treatment. PATIENTS AND INTERVENTION: We recruited six adults (median age 54); three with a WNT1 missense mutation c.652T>G and three with a PLS3 splice mutation c...
October 12, 2016: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/27732325/stress-fractures-concepts-and-therapeutics
#16
Carolina A Moreira, John P Bilezikian
CONTEXT: Stress fractures are repetitive use injuries in which recurrent strains lead to material fatigue and microarchitectural discontinuities. Stress fractures account for up to 20% of athletic injuries, more commonly sustained by women and in those who engage in track-and-field events. The pathogenesis of stress fractures is multifactorial. Although most stress fracture are reported among women who may experience menstrual disturbances, low body mass index, low energy intake and sometimes low bone mass, these individuals do not regularly seek endocrinological attention...
October 12, 2016: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/27708978/teriparatide-for-the-rapid-resolution-of-delayed-healing-of-atypical-fractures-associated-with-long-term-bisphosphonate-use
#17
Silvina R Mastaglia, Gabriel Aguilar, Beatriz Oliveri
Bisphosphonates (BPs) are the most widely used drugs to treat osteoporosis. However, recent reports associated to long-term BPs use with atypical low-impact fractures and prodromal pain. It is estimated that 26% of the cases of atypical fractures associated with the long-term use of BPs show delayed healing or nonunion. Teriparatide [PTH1-34] (TPTD) is an anabolic drug shown to be effective in stimulating bone formation. The aim was to describe the course of a right diaphyseal femoral fracture sustained by a patient on long-term BPs treatment...
June 2016: Eur J Rheumatol
https://www.readbyqxmd.com/read/27681935/postmenopausal-osteoporosis
#18
Richard Eastell, Terence W O'Neill, Lorenz C Hofbauer, Bente Langdahl, Ian R Reid, Deborah T Gold, Steven R Cummings
Osteoporosis is a metabolic bone disorder that is characterized by low bone mass and micro-architectural deterioration of bone tissue. Fractures of the proximal femur, the vertebrae and the distal radius are the most frequent osteoporotic fractures, although most fractures in the elderly are probably at least partly related to bone fragility. The incidence of fractures varies greatly by country, but on average up to 50% of women >50 years of age are at risk of fractures. Fractures severely affect the quality of life of an individual and are becoming a major public health problem owing to the ageing population...
2016: Nature Reviews. Disease Primers
https://www.readbyqxmd.com/read/27645108/challenges-in-studying-very-rare-cancer-outcomes-and-infrequent-exposures-example-of-teriparatide-and-osteosarcoma
#19
Elizabeth B Andrews, Alicia Gilsenan, Kirk Midkiff, David Harris
No abstract text is available yet for this article.
August 31, 2016: Annals of Epidemiology
https://www.readbyqxmd.com/read/27630919/osseous-consolidation-of-an-aseptic-delayed-union-of-a-lower-leg-fracture-after-parathyroid-hormone-therapy-a-case-report
#20
Ilko Kastirr, Sebastian Radmer, Reimer Andresen, Hans-Christof Schober
The absence of osseous consolidation of a fracture within the normal time period is defined as delayed union or non-union. Both for the patient and from a socio-economic point of view, impaired fracture healing represents a major problem. Risk factors for a delayed fracture healing are insufficient immobilisation, poor adaptation of the fracture surfaces, interposition of soft tissue in the fracture gap, as well as circulation disturbances, metabolic disease, smoking and infections. In animal studies, a positive effect of parathyroid hormone (PTH) on fracture healing has been shown...
July 2016: Journal of Clinical and Diagnostic Research: JCDR
keyword
keyword
112
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"